Investors

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities.
More>>
Featured Reports
2015 Annual Report on Form 10-K - PDF 2015 Annual Report on Form 10-K
OSUR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$8.31
Change (%) Stock is Down 0.18 (2.12%)
Volume689,699
Data as of 09/23/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
09/06/16OraSure Technologies to Present at the CL King 14th Annual Best Ideas Conference
BETHLEHEM, Pa., Sept. 06, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the CL King 14th Annual Best Ideas Conference in New York. The conference will be simultaneously webcast over the Internet. Mr. Michels is scheduled to speak on September 13, 2016, at approximately 10:15 AM Eastern Time (7:1... 
Printer Friendly Version
08/29/16DNA Genotek’s OMNIgene®Ÿ GUT Kit is Proposed as Standardized Test for Worldwide Studies of the Human Microbiome
Human Longevity Inc. Study on OMNIgene®Ÿ GUT Recently Published in Scientific Reports BETHLEHEM, Pa., Aug. 29, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that a study conducted by Human Longevity, Inc. (HLI) and published in the Journal Scientific Reports (Nature Publishing Group) on August 25, 2016 proposes the use of the OMNIgene•GUT microbiome sample collection and stabilization device sold by OraSure’s wholly-owned subsidiary, DNA Genotek Inc., in gl... 
Printer Friendly Version
08/23/16OraSure Awarded Up to $16.6 Million to Advance Rapid Zika Tests
BETHLEHEM, Pa., Aug. 23, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, announced today that it has been awarded a contract for up to $16.6 million in total funding from the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (BARDA) to advance the Company’s rapid Zika tests. Th... 
Printer Friendly Version
08/03/16OraSure Announces 2016 Second Quarter Financial Results
BETHLEHEM, Pa., Aug. 03, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the three and six months ended June 30, 2016. Financial Highlights Consolidated net revenues for the second quarter of 2016 were $31.4 million, a 3% increase from the second quarter of 2015. Consolidated net revenues for the six months ended June 30, 2016 were $60.4 ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources



Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet